Cue Biopharma Announces $30 Million Private Placement
Rhea-AI Summary
Cue Biopharma (NASDAQ: CUE) announced a private placement expected to raise approximately $30 million in gross proceeds via pre-funded warrants and accompanying warrants. The PIPE is expected to close on or about May 4, 2026, subject to customary conditions and stockholder approval.
Proceeds are intended to advance the clinical pipeline, including acquiring and developing Ascendant-221, and for working capital and general corporate purposes. Newbridge Securities is placement agent; resale registration will be filed with the SEC.
Positive
- Gross proceeds of approximately $30 million to fund operations and pipeline
- Transaction structured with pre-funded warrants enabling near-term capital commitment
- Proceeds earmarked to acquire and develop Ascendant-221
Negative
- Up to 4,090,908 shares issuable on exercise could dilute existing shareholders
- PIPE requires stockholder approval before pre-funded warrants become exercisable
- Warrants expire on the fifth anniversary of closing, limiting long-term conversion timing
News Market Reaction – CUE
In the May 1 session, CUE gained 106.38%, reflecting a significant positive market reaction. Argus tracked a peak move of +206.2% during that session. Our momentum scanner triggered 101 alerts that day, indicating very high trading interest and price volatility. Trading volume was exceptionally heavy at 16.4x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Reverse stock split | Negative | -6.0% | 1-for-30 reverse split to regain Nasdaq bid price compliance. |
| Apr 15 | Preclinical data | Positive | +65.4% | New preclinical data on lead autoimmune candidate CUE-401 at IMMUNOLOGY2026. |
| Apr 08 | Milestone payment | Positive | +45.5% | $7.5M preclinical milestone from Boehringer Ingelheim collaboration for CUE-501. |
| Mar 27 | CEO transition | Negative | -5.6% | Interim CEO appointment and leadership change amid efforts to advance CUE-401. |
| Mar 26 | R&D day event | Positive | -5.0% | Announcement of virtual R&D Day focusing on CUE-401 research and Q&A. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows sharp positive reactions to R&D and partnership milestones and negative reactions to balance-sheet and governance events (reverse split, leadership changes). Most past moves aligned with the qualitative tone of the news, with the R&D Day announcement being a notable divergence.
Over the past months, CUE has reported several key events. A 1-for-30 reverse stock split on Apr 22 was followed by a -5.97% move. Preclinical and collaboration news on CUE-401 and CUE-501, including a $7.5 million milestone, saw strong gains of 45.48% and 65.37%. Governance changes around the interim CEO on Mar 27 aligned with a -5.6% move. Today’s private placement follows this pattern of financing and balance-sheet focused news after sizable R&D-driven rallies.
Key Terms
private placement financial
pre-funded warrants financial
warrants financial
accredited investors regulatory
registration statement regulatory
resale registration statement regulatory
placement agent financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, announced today that it has entered into a securities purchase agreement with certain accredited investors for a private placement (the “PIPE financing”) for gross proceeds of approximately
Newbridge Securities Corporation is acting as placement agent for the PIPE financing.
In the PIPE financing, Cue Biopharma agreed to sell pre-funded warrants (“Pre-Funded Warrants”) to purchase an aggregate of up to 2,727,272 shares of common stock and accompanying common stock warrants (“Warrants”) to purchase an aggregate of up to 1,363,636 shares of common stock (or, in certain circumstances, Pre-Funded Warrants) at an effective price of
The Pre-Funded Warrants are exercisable at any time following receipt of approval by the Company’s stockholders at an upcoming special meeting of the Company’s stockholders (“Stockholder Approval”) and will not expire. The Warrants are exercisable following receipt of Stockholder Approval and will expire on the fifth anniversary of the closing of the PIPE financing.
Net proceeds from the PIPE financing are expected to be used to advance the Company’s clinical pipeline, including acquiring and developing Ascendant-221, working capital and other general corporate purposes.
The securities to be sold in the PIPE financing have not been registered under the Securities Act of 1933, as amended (“Securities Act”), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Cue Biopharma has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issuable upon the exercise of the Pre-Funded Warrants and Warrants issued in the PIPE financing.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.
About Cue Biopharma
Cue Biopharma (Nasdaq: CUE) is a clinical stage therapeutics company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset is a novel anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company’s statements about the expected closing of the PIPE financing; the company’s anticipated use of proceeds from the PIPE financing; whether the conditions for the closing of the PIPE financing will be satisfied; expectations with respect to obtaining the Stockholder Approval; and the company’s business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Cue Biopharma may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Cue Biopharma makes as a result of various risks and uncertainties, including, among others, risks related to the satisfaction of customary closing conditions related to the PIPE financing and the impact of general economic, industry or political conditions in the United States or internationally and the other risks and uncertainties described in the Risk Factors sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor and Media Contact
Marie Campinell
Agnes Lee
ir@cuebio.com
Cue Biopharma, Inc.
